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Background: The prevalence of chronic suppurative lung disease (CSLD) and bronchiectasis unrelated to cystic
fibrosis (CF) among Indigenous children in Australia, New Zealand and Alaska is very high. Antibiotics are a major
component of treatment and are used both on a short or long-term basis. One aim of long-term or maintenance
antibiotics is to reduce the frequency of acute pulmonary exacerbations and symptoms. However, there are few
studies investigating the efficacy of long-term antibiotic use for CSLD and non-CF bronchiectasis among children.
This study tests the hypothesis that azithromycin administered once a week as maintenance antibiotic treatment
will reduce the rate of pulmonary exacerbations in Indigenous children with bronchiectasis.
Methods/design: We are conducting a multicentre, randomised, double-blind, placebo controlled clinical trial in
Australia and New Zealand. Inclusion criteria are: Aboriginal, Torres Strait Islander, Maori or Pacific Island children
aged 1 to 8 years, diagnosed with bronchiectasis (or probable bronchiectasis) with no underlying disease identified
(such as CF or primary immunodeficiency), and having had at least one episode of pulmonary exacerbation in the
last 12 months. After informed consent, children are randomised to receive either azithromycin (30 mg/kg once a
week) or placebo (once a week) for 12–24 months from study entry. Primary outcomes are the rate of pulmonary
exacerbations and time to pulmonary exacerbation determined by review of patient medical records. Secondary
outcomes include length and severity of pulmonary exacerbation episodes, changes in growth, school loss,
respiratory symptoms, forced expiratory volume in 1-second (FEV1; for children ≥6 years), and sputum
characteristics. Safety endpoints include serious adverse events. Antibiotic resistance in respiratory bacterial
pathogens colonising the nasopharynx is monitored. Data derived from medical records and clinical assessments
every 3 to 4 months for up to 24 months from study entry are recorded on standardised forms.
Discussion: Should this trial demonstrate that azithromycin is efficacious in reducing the number of pulmonary
exacerbations, it will provide a much-needed rationale for the use of long-term antibiotics in the medical
management of bronchiectasis in Indigenous children.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12610000383066
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Internationally, the burden of ill health from acute and
chronic respiratory disease remains high in Indigenous
populations [1-5]. While childhood chronic suppurative
lung disease (CSLD), including bronchiectasis unrelated
to underlying causes such as cystic fibrosis (CF) are
much less common than a century ago, evidence is
emerging of increasing prevalence in recent decades
[6,7]. These chronic pulmonary disorders remain im-
portant in low and middle-income countries [8] and
within disadvantaged population groups in high-income
nations [9]. In these groups, bronchiectasis is associated
with very high rates of childhood pneumonia and other
acute respiratory infections (e.g. bronchiolitis) [10,11].
The prevalence of non-CF bronchiectasis among Indi-
genous children from remote communities in Australia
is 1470/100,000 children [3]. Equivalent rates for Maori
and Pacific Island children in New Zealand and for Al-
aska Native children from the Yukon Kuskokwim Delta
region are 63, 154 and 1400–2000 per 100,000 children
respectively [4,5]. In contrast, the estimated prevalence
rates of bronchiectasis amongst New Zealand children
under 15 years of age is 33 per 100,000 [5].
Bronchiectasis is a disease characterized by abnormal
irreversible bronchial dilatation, which is associated with
chronic bacterial infection and inflammation. ‘Symp-
toms’ include persistent ‘moist’ cough, mucopurulent
sputum, haemoptysis, and breathlessness [2,12]. The
current ‘gold standard’ for diagnosis is confirmation by a
high-resolution computed tomography (HRCT) scan of
the chest [13]. This investigation however, is not readily
available in all settings. Bronchiectasis is considered
within the spectrum of CSLD, which includes children
with these same symptoms, but who lack HRCT scan
evidence of bronchiectasis (either because of limited op-
portunity of testing or inability to meet the current
HRCT scan adult criteria) [14]. Nonetheless, without
treatment children with CSLD may continue to have
persistent respiratory symptoms and progress to meet
the radiological criteria for bronchiectasis [14]. Treat-
ment aims at resolving acute infection and/or control-
ling established infection and inflammation, thus
improving symptoms, reducing frequency of acute pul-
monary exacerbations, preserving respiratory tissue and
lung function, optimising growth, and improving quality
of life (QoL) [14,15]. As bacteria such as Haemophilus
influenzae, Streptococcus pneumoniae and Moraxella
catarrhalis are believed to play a central role in the
pathogenesis of CSLD and bronchiectasis [16] antibiotics
are used to reduce the bacterial load and the associated
lower airway inflammation [14]. Pulmonary exacerba-
tions often require hospital-based treatment with intra-
venous antibiotics and intensive physiotherapy.
Furthermore, severe pulmonary exacerbations are anindependent risk factor for long-term lung function de-
cline in children with bronchiectasis [17]. Long-term use
of antibiotics may provide a benefit by reducing exacer-
bations, but are not recommended currently as part of
routine treatment [14]. A recent Cochrane Review of 10
randomised, controlled trials (RCTs) involving 959 chil-
dren and adults with CF reported a modest improve-
ment in pulmonary function measured as forced
expiratory volume in 1-second (FEV1) after 6 months of
azithromycin, reduced pulmonary exacerbation rates and
improved weight gains [18]. Azithromycin was well tol-
erated and while it was associated with decreased
Staphylococcus aureus isolation rates in respiratory cul-
tures, there was also a significant increase in macrolide
resistance. In contrast, so far there are no published
RCTs investigating the efficacy of long-term antibiotic
use in children with non-CF bronchiectasis.
Following the methodological rigour outlined in the
CONSORT statement, [19] we describe the methods of
our Bronchiectasis Interventional Study (BIS), a multi-
centre, double-blind, RCT examining the efficacy and
safety of maintenance azithromycin treatment (30 mg/kg
once a week) versus placebo for 12–24 months in Indi-
genous children with non-CF bronchiectasis.Study aims
Our primary question is: among Indigenous children
with bronchiectasis, can long-term (12–24 months) azi-
thromycin treatment reduce the frequency of pulmonary
exacerbations compared to placebo? Our secondary
questions are: (i) does long-term azithromycin treatment
reduce the length of hospitalised pulmonary exacerba-
tions and severity of pulmonary exacerbations, improve
growth, decrease school absenteeism, and improve re-
spiratory symptoms, pulmonary function as measured by
FEV1 (≥6 years), and sputum characteristics? (ii) is azi-
thromycin associated with any serious adverse events
(SAEs) or with increased antibiotic resistance in respira-
tory bacterial pathogens in the nasopharynx?
Our study tests the primary hypothesis that long-term
(12–24 months) antibiotic treatment with azithromycin
reduces the rate of pulmonary exacerbations in Indigen-
ous children with non-CF bronchiectasis.Methods
Participants and settings
This RCT is being conducted in Australia and New Zea-
land. Australian Aboriginal and Torres Strait Islander
children from the Anangu Pitjantjatjara lands (Central
Australia), the northern regions of the Northern Terri-
tory (NT) and the Torres Strait in Australia, and Maori
and Pacific Island children from the greater Auckland
region of New Zealand with bronchiectasis, are enrolled.
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Inclusion criteria: (i) Self or caregiver ascribed Aborigi-
nal, Torres Strait Islander, Maori or Pacific Island chil-
dren, aged between 1 and 8 years; (ii) living currently
within the study catchment community; (iii) with either
a confirmed HRCT scan diagnosis of bronchiectasis or a
clinical diagnosis of bronchiectasis (probable bronchiec-
tasis, but no HRCT scan available) after clinical review
and other appropriate investigations have been com-
pleted (including full blood count, immune function
tests and sweat test, chest x-ray, and when indicated
contrast-videoflouroscopy) [14,20] without a specific
underlying cause identified e.g. CF, primary immunodefi-
ciency, primary ciliary dyskinesia or primary aspiration,
and (iv) having had at least one episode of pulmonary
exacerbation in the last 12 months.
Exclusion criteria: (i) children receiving chemotherapy,
immunosuppressive treatment or long-term antibiotic
use, (ii) those with an identified underlying cause of their
CSLD or bronchiectasis (e.g. CF, primary immunodefi-
ciency, ciliary dyskinesia or primary aspiration), (iii)
those with other disorders (e.g. renal or hepatic failure,Intervention period
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Figure 1 Participant flow diagram.diabetes, central nervous system or neuromuscular dis-
order, congenital cardiac abnormality), or (iv) a history
of macrolide hypersensitivity.
If the local doctor (or paediatrician) decided that
‘long-term antibiotics or long-term placebo’ was not ap-
propriate at the time (‘too well’ or ‘too sick’ to be rando-
mised), the child was reassessed at a later stage and, if
appropriate, was enrolled into the study at that time.
Children already receiving long-term antibiotics may be
randomised after they had discontinued antibiotics for at
least 2 weeks.
Recruitment
Caregivers of eligible children were approached and
informed consent obtained between November 2008 and
December 2010. The CONSORT flow diagram and the
accompanying timelines, outcomes and procedures are
displayed in Figures 1 and 2 respectively. At the end of
the intervention period (12 to 24 months), children are
followed for a further 6 months. Except for the number
of children assessed for eligibility, the design is consist-
ent with the CONSORT statement of 2010 [19]gible
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Past medical history 
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Demographics
Cough
Clinical assessment
Height and weight
Deep nasal swab
Diagnosis
Subsequent assessments:
Cough
Clinical assessment
Height and weight
Deep nasal swab
Diagnosis
Primary outcomes: 
- Counts of exacerbation episodes (enrolment to end of intervention)
- Time to exacerbation (enrolment to 1st exacerbation episode)
Secondary outcomes:
- Length of exacerbation episodes (length of hospital stay)
- Severity of exacerbation episodes (hospitalised vs. treated at home)
- Growth (z-scores at baseline vs. at the end of intervention)
- Overall well being (proportion of visits where wet cough was present)
- Serious adverse effects
- Antibiotic resistance by respiratory bacterial pathogens (Streptococcus pneumoniae, Haemophilus 
influenzae, Moraxella catarrhalis, Staphylococcus aureus and Streptococcus pyogenes) at baseline and at 
the end of the intervention against macrolide and beta-lactam antibiotics.
Subsequent assessments (every 3-4 months) 
Figure 2 Outcome variables and time-points of assessment.
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Indigenous children in the communities included in the
study, and the >2 year recruitment period, it was not
feasible to collect information on all children assessed
for eligibility. Follow-up assessments associated with the
study are expected to be completed by late 2012.
Follow-up schedule
Three full-time research nurses, based in Alice Springs
and Darwin, NT, Australia, and Auckland, New Zealand,
are responsible for the day-to-day management of study
participants, and liaison with the co-ordinating centre
based in Brisbane, Australia. Every 3–4 months, each
study participant is asked to attend a study clinic. In
Australia, clinics are held at local community clinics in
13 Indigenous communities (5 in the northern region of
the NT, 6 in central Australia, 2 in the Torres Strait). In
New Zealand, clinics are held at the Starship Children’s
Health, Auckland City Hospital. Each subject receives at
least 4 clinic reviews a year, including 2 by the study
paediatrician and 2 by the research nurse.
Subject efficacy withdrawal criteria
The following intervention ‘exit criteria’ (in case of
‘treatment failure’) are being used: the maximum num-
bers of pulmonary exacerbations allowed in any
12 month period are either 6 episodes treated by the
local clinic (as an outpatient) or 4 hospital admissions.Children meeting the exit criteria are withdrawn from
the intervention study, but continue to be followed until
the end of the trial period. In addition, the local clinician
or local investigator is able to withdraw a participant at
any time. Children withdrawn from the study will not be
replaced. Children exiting the study due to excess
exacerbations are offered to go onto open label medica-
tion until the end of the study.
Study medication
Azithromycin is purchased from Pfizer and rebottled by
the Institute of Drug Technology (IDT, Melbourne). The
placebo medication is also manufactured by IDT, Mel-
bourne according to Australian standards and is similar
in appearance, taste, smell and packaging to the active
drug in order to maintain blinding during the study
period. Prior to administering the trial medications, 9
mls of water is added to the bottle after piercing the alu-
minium foil making a total volume of 15 mls per bottle;
0.75 mls/kg (30 mg/kg/week for azithromycin) are given
once weekly (maximum of 15mls). Each bottle is used
only once and it and the remaining medication are then
discarded.
Randomisation, allocation and blinding
A computer generated permuted block design provided
the randomisation sequences stratified by study site
(Australia and New Zealand) and number of
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episodes vs. ≥3 episodes; Figure 1). A computer gener-
ated 3 digit number was used as the randomisation iden-
tification number. A treatment code (A to F) was
allocated to each randomisation number. Only the inde-
pendent statistician and IDT knew the codes. An inde-
pendent person at the Queensland Institute of Medical
Research (QIMR), Brisbane, Australia prepared individ-
ual envelopes labelled with the randomisation number
and containing the corresponding treatment code inside.
Allocation concealment was achieved by use of sequen-
tially numbered sealed opaque envelopes. All treatment
bottles are labelled identically for each child. Patients,
their families, care providers and investigators collecting
data are unaware of the treatment assigned to each
child.
Administration of the study medication and compliance
In Australia, Aboriginal and Torres Strait Islander chil-
dren included in the study predominantly live in small
remote communities of 200 to 1000 people. Study medi-
cation is administered under direct supervision at the
community clinics. At numerous communities, local
community workers are employed to locate the children
weekly and dispense study medication. They contact the
study nurse weekly to advise on the details about medi-
cation adherence (children receiving medication and, if
any, children are absent from the community), and any
issues around administration such as vomiting, “spitting
up” the medication, abdominal pain or diarrhoea. These
data are recorded in the ‘Participant Medication Log
Book’.
In New Zealand, Maori and Pacific Island children
included in the study mostly live in an urban environ-
ment in the greater Auckland region. Study medication
is administered under direct supervision at the partici-
pant’s school, preschool or at their home. A whanau
(support) worker is employed to assist with recruitment,
informed consent, and to deliver and dispense study
medication. The whanau worker records in the ‘Partici-
pant Medication Log Book’ the details about medication
adherence and any issues around administration.
Study endpoints
Primary outcomes: (i) rate of pulmonary exacerbations
(treated as an outpatient or in hospital) and (ii) time to
next pulmonary exacerbation. Each endpoint is deter-
mined by reviewing the patient and medical records.
Secondary outcomes: length of pulmonary exacerba-
tion episodes; severity of pulmonary exacerbations (hos-
pitalisation, oxygen requirement); change in growth
(height, weight); respiratory symptoms (standardised
questionnaire), sputum characteristics (a standardised
and validated colour chart (Bronkotest colour chart) isused to grade sputum visually) [21], school absenteeism,
FEV1 in those aged ≥ 6 years; and safety endpoints (ser-
ious adverse events (SAEs). Antibiotic resistance in re-
spiratory bacterial pathogens detected in nasopharyngeal
(deep nasal) swabs are also monitored.
Data are collected at 3 to 4 month intervals from med-
ical records and clinical assessments (when possible) for
up to 30 months from study entry (Figure 2).
Outcome measurements and time point of assessments
The medical records of participating children (at the
community clinic and the hospital) are monitored
throughout the duration of the study. Information about
primary study endpoints, other outcome measures, as
well as follow-up visits (e.g. symptoms, clinical assess-
ment, anthropometric measurements) are extracted
from these records. Figure 2 lists the main outcome vari-
ables and the assessment time-points. Data are collected
on standardised forms and entered into an Access data-
base subject to internal range and logic checks to min-
imise errors. Data are then entered locally into a
password-protected study database, on a secure website.
An Australian-based data manager conducts regular data
checks and queries to ensure data completeness and ac-
curacy. Investigators and research nurses meet regularly
to discuss data collection issues and study progress.
Safety measurements
Serious adverse events
An independent Data Safety Monitoring Board (DSMB)
was established to monitor data throughout the duration
of the study and to determine whether it should be dis-
continued on scientific or ethical grounds. The DSMB
monitors the clinical trial in accordance with the World
Medical Association Declaration of Helsinki – Ethical
Principles for Medical Research Involving Human Sub-
jects, [22] as well as the Australian National Health and
Medical Research Council National Statement on Ethical
Conduct in Research Involving Humans (2007) and
Values and Ethics: Guidelines of Ethical Conduct in
Aboriginal and Torres Strait Islander Health Research
[23].
SAEs include any untoward medical occurrence that
results in death or is life threatening, results in signifi-
cant disability/incapacity, requires inpatient hospitalisa-
tion or prolongation of existing hospitalisation. All SAEs
are reported immediately by telephone to the Chief In-
vestigator (CI) (study paediatrician in charge: PSM,
Royal Darwin Hospital, Australia and CAB, Starship
Children’s Health, New Zealand) and by fax to the Clin-
ical Trial Coordinator (using a standardised SAE form).
All SAEs are investigated by the CI in consultation with
an Independent Safety Monitor (Dr Ngiare Brown, Aus-
tralia and Dr Lesley Voss, New Zealand). Causality is
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Possible, Unlikely, Unrelated, and Unclassifiable. SAEs
with a causality classification of “very likely/certain”,
“probable” or “possible” are reported to the Chair of the
DSMB within 24 hours of their determination and the
medication is withdrawn immediately, although the child
will still remain in the trial. Other causality classifica-
tions are reported to the DSMB in summary format
within 30 days, while all other adverse events are
reported to CIs 3-monthly and are then submitted elec-
tronically to the DSMB Independent Safety Monitor.
Bacteriology, including antibiotic resistance
At enrolment, and when possible at clinic reviews and
hospital admissions, participants have a deep nasal swab
collected as described previously [24]. Swabs of aural
discharge are also taken if a discharging perforation of
the eardrum is present. Swabs are placed into a tube
containing 1 mL of skim-milk tryptone glucose glycerol
broth (STGGB), [24] and are either transported frozen if
taken during community visits or sent to the laboratory
immediately on ice if collected while in hospital. All spe-
cimens are stored at -80°C until testing.
Culturing, identifying and serotyping common respira-
tory bacteria from nasal swabs are established techni-
ques in our laboratory [24]. Batches of swabs are thawed
and 10uL aliquots cultured overnight on selective media
at 37°C in 5% CO2. S. pneumoniae, H. influenzae, M.
catarrhalis, S. aureus and Streptococcus pyogenes are
identified using standard techniques [25]. S. pneumoniae
isolates are serotyped using the Quellung method (anti-
sera from Statens Serum Institute, Denmark).
Antibiotic susceptibility testing is undertaken initially
on 4 colonies each of S. pneumoniae, H. influenzae, S.
pyogenes and S. aureus using the calibrated disc sensitiv-
ity method [24]. When the inhibition zone indicates
reduced antibiotic susceptibility to azithromycin, ampi-
cillin and/or oxacillin, minimum inhibitory concentra-
tions (MICs) are determined by EtestW strips (AB
bioMérieux, Sweden) and resistance to azithromycin,
erythromycin, penicillin and ampicillin as appropriate
for the pathogen of interest is defined according to the
European Committee on Antimicrobial Susceptibility
Testing (EUCAST) breakpoints (http://www.eucast.org).
A nitrocephin-based test detects beta-lactamase activity
in H. influenzae and M. catarrhalis isolates.
Sample size calculation
The study sample size and power calculations were
based on our Central Australia data [11] where Indigen-
ous children diagnosed with bronchiectasis had on aver-
age 1 pulmonary exacerbation every 6 months (standard
deviation = 5.4) that required hospital admission. Thus,
the ‘placebo’ group is expected to have 4 episodesinvolving hospital management during the 24-months of
the trial intervention. Assuming the intervention reduces
the number of pulmonary exacerbations leading to hos-
pitalisation by 50% (from 4 to 2 episodes) and that the
placebo group have a 15% reduction in hospitalised pul-
monary exacerbations (from 4 to 3.4 episodes), then with
51 subjects in each group there is 95% power to detect
an average difference of −1.4 respiratory hospital admis-
sions per subject over a 2 year period between the inter-
vention and placebo groups at the 5% level of
significance. Importantly, these estimates used hospita-
lised exacerbation rates as a conservative estimate of
total exacerbation rates (hospital management and those
treated at the local clinic as outpatients). The sample
size required to estimate the difference between the rate
parameters of 2 Poisson distributions over 24 months
with 90% power was 34 observations from each sample
(68 child-years at risk in each group).
Data analysis
Data will be analysed using the statistical software pack-
age SPSS (IBM SPSS Statistics Version 20) and presented
in accordance with the CONSORT statement [19]. All
tests will be two-tailed, and statistical significance will be
set at p <0.05. Study end points experienced for each
treatment group will be formally analyse [26] on an
"intention to treat" basis. Important potential confoun-
ders will be included in a secondary multivariate ana-
lysis. Basic descriptive summaries will be compiled for
each treatment group. For continuous normally-
distributed variables we will report means and compare
groups using a t-test for independent samples. For non-
normally-distributed data we will report medians and
use non-parametric tests. If rates of exacerbation are
consistent with a Poisson distribution, they will be
assessed using Poisson regression. Categorical data will
be analysed using the Chi-squared tests and Fisher’s
exact test (2-tailed), as appropriate. Time to first exacer-
bation will be assessed using Cox proportional hazards
regression and graphically displayed using Kaplan-Meier
estimates. In addition, Epi Info (version 3.5.3) will be uti-
lised to calculate growth z-scores. Children will be clas-
sified as stunted or underweight if their enrolment
‘height-for-age’ or ‘weight-for-age’ z-scores are less than
−1.96, respectively, which indicate that the values are
more than 2 standard deviations (SDs) below the corre-
sponding population means.
Ethical approval
Ethical approval has been obtained from the respective
Human Ethics Committees of all participating institu-
tions [Queensland Institute of Medical Research, Auck-
land District Health Board, the Northern Territories
Department of Health and Community Services and
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Human Ethics Committee, and the Children's Health
Queensland Hospital and Health Service].
Discussion
Antibiotics are one of the main therapies used to treat
bronchiectasis, both during acute pulmonary exacerba-
tions, and in some patients as long-term maintenance
treatment during the chronic stable phase. Based on
Cole’s ‘vicious cycle’ model of the pathophysiology of
bronchiectasis, [27] antibiotic treatments are recom-
mended to reduce the bacterial load, which then de-
crease lower airway inflammation. Brief antibiotic
interventions significantly improve airway [28,29] and
systemic [28,29] inflammatory profiles, as well as im-
proving QoL measures [29,30]. For the chronic stable
phase, cohort studies [31,32] support the use of pro-
longed antibiotics for reducing exacerbations and spu-
tum purulence, but there are only very limited data from
RCTs to justify this approach [33].
The rationale for choosing azithromycin includes its
recognised antimicrobial effects, its putative in-vivo
immuno-modulatory and anti-inflammatory actions, and
its unique pharmacological properties, which suggest
once weekly oral dosing (30–40 hours half-life in chil-
dren) may be effective [34-37]. In non-CF bronchiec-
tasis, a cohort study [31] and one short term RCT
(6 months) described improvement in lung function and
reduction in pulmonary exacerbations when azithromy-
cin was given to adults with bronchiectasis. In both
studies, [31,38] the exacerbation frequency rate while
taking regular azithromycin was significantly reduced
(count ratio 0.5-0.7). However, to date there are no RCTs
beyond 6 months and there are no studies of azithromy-
cin in children with non-CF bronchiectasis.
The long half-life of azithromycin, allowing once
weekly dosing is advantageous for adherence and even
directly supervised administration, which is necessary
for the feasibility and sustainability of long-term pro-
grammes involving maintenance antibiotic treatment in
some settings. Any positive aspects of treatment must
however be weighed against the possibility of increased
antibiotic resistance amongst bacterial pathogens in the
respiratory tract, particularly H. influenzae, S. pneumo-
niae, S. pyogenes and S. aureus [39]. The underlying
mechanisms of macrolide resistance can confer either
low or high-level resistance to individual members of
this antibiotic class. Azithromycin is also associated with
increased risk of resistance to other antibiotic classes, es-
pecially the beta-lactams, in respiratory bacterial flora
[40]. While resistance is problematic and treatment fail-
ure has been reported, [41-43] macrolides still play an
important role in managing many infectious diseases, in-
cluding other respiratory infections, trachoma andsexually transmitted infections [44,45]. The current
study is carefully monitoring antibiotic resistance in po-
tential respiratory bacterial pathogens colonising the
nasopharynx.
The reason for choosing pulmonary exacerbations as
our primary outcome is two-fold. Firstly, in chronic re-
spiratory disease (e.g. asthma and chronic obstructive
pulmonary disease), pulmonary exacerbations are an im-
portant end point in clinical studies and most treatment
strategies aim to reduce their frequency. Secondly, in a
longitudinal cohort study in children with non-CF bron-
chiectasis, the only significant predictor of FEV1 decline
(over 3-yrs) was frequency of hospitalised exacerbations
[17]. With each exacerbation, the FEV1 % predicted
decreased significantly by 1.95% adjusted for time. In
adults with bronchiectasis, the determinants of acceler-
ated lung function decline are frequency of hospitalised
exacerbations, increased systemic inflammatory markers
and colonisation with P. aeruginosa [46]. Increased mor-
tality risk is also associated with the degree of lung func-
tion impairment [47]. Thus interventions that can
reduce pulmonary exacerbations are likely to be import-
ant for preventing future adult lung dysfunction [48] in
addition to reducing the economic and social costs asso-
ciated with each episode [49]. Furthermore, recurrent
exacerbations are one of the strongest predictors of poor
QoL in adults with bronchiectasis [50]. This is consistent
with data for asthma describing pulmonary exacerba-
tions in childhood and adult asthma associated with
accelerated FEV1 decline in those not receiving pre-
ventative therapy [51]. Thirdly, in children at this very
young age respiratory exacerbations can be readily
recorded, unlike some other outcome measures.
Strengths of our study include its randomised trial de-
sign, the inclusion of local community workers, and
monitoring of adherence. This study is being undertaken
in two very different settings: in Australia the study is
being conducted mostly in remote, rural Indigenous
communities with limited healthcare provision, while in
New Zealand the study is being performed in a tertiary
hospital in a large urban setting. The study design
should help to reduce the potential limitation of hetero-
geneity in study settings by stratifying by site during ran-
domisation and also by using standardised inclusion/
exclusion criteria and data collection procedures and
forms. Regular meetings between research personnel to
discuss data collection issues and study progress should
also help to ensure very good standardisation of the data
collection procedures across study sites. The use of local
community workers to aid recruitment, administer study
medicine and address adherence directly will also assist
in the successful conduct of the study. In Australia and
New Zealand, study medication is administered to parti-
cipants under direct supervision by either health clinic
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any issues around administration are carefully recorded
on standard forms. This ensures good documentation of
adherence with study medication.
A potential limitation of our study is that it is under-
powered for small differences between groups. Neverthe-
less, even though our final enrolment of participants
(n = 89) was less than the calculated target (n = 102), it
still provides 90% power to detect statistically significant
differences between the intervention and placebo
groups.
Internationally, Indigenous children continue to have
very high rates of chronic respiratory diseases, including
bronchiectasis. If efficacious, a treatment regime of
maintenance azithromycin to reduce the frequency of
pulmonary exacerbations in Indigenous children with
CSLD, including non-CF bronchiectasis is attractive as it
is simple to administer It could substantially improve
the prognosis of Indigenous children with bronchiectasis
and would be a substantial advance in the treatment of
these infants and children.
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